|
Market Closed -
Other stock markets
|
After hours 01:47:32 am | |||
| 130.86 USD | +0.40% |
|
128.93 | -1.47% |
| 06:59pm | Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating | MT |
| 22/07 | What Bundibugyo Ebola vaccines and treatments are under development | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | Other Pharmaceuticals | +0.40% | -3.99% | +6.62% | +15.23% | +89.60% | 16TCr |  |  | |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
